194 related articles for article (PubMed ID: 25034485)
1. Antiviral therapy of chronic hepatitis B.
van Bömmel F; Berg T
Intervirology; 2014; 57(3-4):171-80. PubMed ID: 25034485
[TBL] [Abstract][Full Text] [Related]
2. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
4. [Resistance in hepatitis B virus].
Sheldon J; Sarmento E Castro R; Soriano V
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():49-55. PubMed ID: 19100231
[TBL] [Abstract][Full Text] [Related]
5. Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS; Keeffe EB
Aliment Pharmacol Ther; 2008 Jul; 28(2):167-77. PubMed ID: 18466358
[TBL] [Abstract][Full Text] [Related]
6. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Buti M
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():32-8. PubMed ID: 19100229
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
He L; Liu X; Zhao Y; Zhang S; Jiang Y; Wang X; Yang Z
Dis Markers; 2017; 2017():7075935. PubMed ID: 28396612
[No Abstract] [Full Text] [Related]
9. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
[TBL] [Abstract][Full Text] [Related]
12. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G
Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608
[TBL] [Abstract][Full Text] [Related]
13. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
Nagata N; Kagawa T; Hirose S; Arase Y; Tsuruya K; Anzai K; Shiraishi K; Mine T
BMC Gastroenterol; 2016 Mar; 16():38. PubMed ID: 26987437
[TBL] [Abstract][Full Text] [Related]
14. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
[TBL] [Abstract][Full Text] [Related]
15. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
17. New treatment of chronic hepatitis B.
Lok AS
Semin Liver Dis; 2004; 24 Suppl 1():77-82. PubMed ID: 15192805
[TBL] [Abstract][Full Text] [Related]
18. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Hadziyannis SJ
Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
[TBL] [Abstract][Full Text] [Related]
19. [Clinical management of patients with chronic hepatitis B virus infection].
Rodríguez M; González-Diéguez ML
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():56-65. PubMed ID: 19100232
[TBL] [Abstract][Full Text] [Related]
20. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Buti M
Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]